Endologix weakness a buying opportunity, says Canaccord Canaccord would use the weakness in Endologix following its preliminary Q3 results as a chance to accumulate the shares. The firm believes the Nellix opportunity remains intact and sees its European performance as a precursor to great things to come for its technology. Canaccord reiterates its Buy rating and $17.50 price target on Endologix shares.
Endologix to initiate prospective randomized EVAR clinical study Endologix announced that it will conduct the first ever prospective randomized clinical study to compare outcomes in endovascular repair of abdominal aortic aneurysms. The LEOPARD Study has been designed to provide an accurate and unbiased assessment of commercially available EVAR devices with a planned enrollment of 600 patients. LEOPARD will include up to 60 active EVAR centers throughout the United States. The primary endpoint of the study is treatment success at one year based upon: procedural success; and rates of freedom from aneurysm rupture; conversion to open surgical repair; endoleaks; clinically significant device migration; aneurysm enlargement and secondary endovascular procedures. Results from the study will be independently adjudicated by a third-party. The follow-up period will be five years.